Leanne Peiser
Immunology and discovery leader with 20+ years advancing pipeline assets from discovery through BLA
- Role
- Board Observer at Be Biopharma
- Location
- Seattle, WA, US
- LinkedIn followers
- 500 followers
About Leanne Peiser
Executive Leadership & Strategic Impact : Seasoned executive with 20+ years leading translational and discovery teams across Amgen, Gilead, FLXBio, and BMS. Currently oversee ~35 scientists at BMS, delivered 30+ IND-enabling packages and clinical insights for cell therapy and immuno-oncology programs. Influenced portfolio decisions through department-wide strategy, BD and governance presentations.Discovery & Translational Excellence: Helped advance >15 novel therapeutics to IND across autoimmune, oncology, and infectious diseases. Delivered and led translational strategy for 40+ clinical-stage programs, supporting 30+ INDs and 9 global submissions across modalities including CAR T, small molecules, ADCs, bispecifics, and immune engagers (TCE, NKE).Regulatory & Global Leadership: Global translational lead for Breyanzi, contributing to BLA filings across 4 approved indications and 9 global submissions. Authored pivotal sections of INDs, sBLAs, and led health authority interactions across US, EU, and APAC.Organizational Development & Talent Growth: Managed and mentored >50 scientists over two decades. Promoted >20 team members, including high-visibility rapid advancement cases recognized in HR and leadership forums. Built resilient, high-performing teams with >90% retention.Cross-Functional & Enterprise Alignment : Served as translational SME across early discovery, BD diligence, and clinical development. Partnered with to shape business investments and partnerships, therapeutic area and clinical development strategies.Scientific & Innovation Leadership: Recognized expert in CAR T biology, macrophages, and MDSCs. Led rationale development for next-gen CART and immunotherapy programs. Piloted GenAI tools for translational data analysis, improving operational efficiency.Global Reach & Strategic Collaborations: Expanded BMS’s cell therapy footprint across hematology, immunology, and oncology. Supported international CTA filingsand strategic collaborations with Stanford University, MDACC, Imperial College among others enhancing scientific visibility and regulatory reach
Experience
Board Observer
Mar 2025 — Present
Education
University of Cape Town
B.Sc (MED)(HONS), Medical Biochemistry
1995 — 1995
University of Cape Town
B.Sc., Microbiology, Biochemistry
1992 — 1994
University of Oxford
D.Phil, Immunology
1996 — 2001
Skills
- In Vitro
- Toxicology
- Immunohistochemistry
- Research
- Biochemistry
- Infectious Diseases
- Flow Cytometry
- Macrophage
- Monoclonal Antibodies
- Immunology
- Assay Development
- Pharmaceutical Industry
- Cell Culture
- Clinical Research
- Biology
- Lifesciences
- Immune Oncology
- Autoimmunity
- Inflammation
- In Vivo
- Cell Biology
- Life Sciences
- Molecular Biology
- Elisa
- Protein Chemistry
- Ind
- Drug Discovery
- Antibodies
- Clinical Development
- Neuroscience
- Western Blotting
- Oncology
- Validation
- Animal Models
- Management
- Immunoncology
- Cell
- Biomarkers
- Biotechnology
- Drug Development
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.